Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer

Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.

Now Viewing

EP: 1.Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer

EP: 2.Unmet Needs of Patients with Locally Advanced Metastatic Urothelial Cancer (mUC)

EP: 3.EV+P Combination Strategy Changing Bladder Cancer Treatment Landscape

EP: 4.SOGUG-AUREA Study Overview

EP: 5.SOGUG-AUREA Trial Results Impacting Next-Steps for Bladder Cancer Treatment

EP: 6.Exploring the Role of Disitamab Vedotin in the Treatment of Metastatic Urothelial Cancer

EP: 7.Penpulimab Plus Anlotinib Evaluated for Previously Treated Urothelial Cancers

Related Videos

Related Content

Advertisement

July 1st 2025

Lower Tregs Linked With Survival in Multiple Myeloma

Jared Kaltwasser

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 1st 2025

Challenges and Opportunities for AI in Melanoma Detection

AJMC Contributor

While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined challenges with these novel approaches.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Brooke McCormick

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

June 27th 2025

Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

Kristi Rosa

Mirvetuximab soravtansine continues to show efficacy and safety in the final analysis of the phase 2 PICCOLO study.

Related Content

Advertisement

July 1st 2025

Lower Tregs Linked With Survival in Multiple Myeloma

Jared Kaltwasser

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 1st 2025

Challenges and Opportunities for AI in Melanoma Detection

AJMC Contributor

While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined challenges with these novel approaches.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Brooke McCormick

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

June 27th 2025

Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

Kristi Rosa

Mirvetuximab soravtansine continues to show efficacy and safety in the final analysis of the phase 2 PICCOLO study.